Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:MLNT

Melinta Therapeutics (MLNT) Stock Price, News & Analysis

Melinta Therapeutics logo

About Melinta Therapeutics Stock (NASDAQ:MLNT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.35
$0.50
52-Week Range
N/A
Volume
N/A
Average Volume
713,628 shs
Market Capitalization
$6.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive MLNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Melinta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MLNT Stock News Headlines

CorMedix signs agreement to acquire Melinta for $300m
Get This Stock Now
This company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardware is so essential that the data center industry uses enough of it to stretch around the world 8 times – in a single building! So, if you own Nvidia stock now, you might be well-served to sell those shares and check out this under-the-radar play instead. Or if you missed the boat on Nvidia, this is a rare second chance to target tremendous profit potential as AI data centers spring up in every corner of the world.tc pixel
SWTX SpringWorks Therapeutics, Inc.
See More Headlines

MLNT Stock Analysis - Frequently Asked Questions

Melinta Therapeutics Inc (NASDAQ:MLNT) announced its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($15.67) earnings per share for the quarter, missing analysts' consensus estimates of ($2.55) by $13.12. The biotechnology company had revenue of $15.87 million for the quarter, compared to analysts' expectations of $15.51 million. Melinta Therapeutics had a negative net margin of 393.39% and a negative trailing twelve-month return on equity of 101.29%.

Melinta Therapeutics's stock reverse split on Friday, February 22nd 2019.The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 21st 2019. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Melinta Therapeutics investors own include Cara Therapeutics (CARA), Clearside Biomedical (CLSD), Chimerix (CMRX), Aerie Pharmaceuticals (AERI), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
11/12/2019
Today
8/24/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MLNT
CIK
1461993
Fax
N/A
Employees
290
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($17.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$157.19 million
Net Margins
-393.39%
Pretax Margin
N/A
Return on Equity
-101.29%
Return on Assets
-28.68%

Debt

Debt-to-Equity Ratio
1.11
Current Ratio
1.03
Quick Ratio
0.72

Sales & Book Value

Annual Sales
$96.43 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$16.96 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
13,750,000
Free Float
N/A
Market Cap
$6.88 million
Optionable
Optionable
Beta
4.16
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:MLNT) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners